Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in R/R CLL/SLL with 17p Deletion (RESONATE-17)
NCT01744691Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Jan 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Pharmacyclics. Started Jan 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01744691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01744691.